PARAGON 28 INC (FNA)
US69913P1057 - Common Stock
Taking everything into account, FNA scores 3 out of 10 in our fundamental rating. FNA was compared to 188 industry peers in the Health Care Equipment & Supplies industry. FNA may be in some trouble as it scores bad on both profitability and health. FNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
FNA had negative earnings in the past year.
In the past year FNA has reported a negative cash flow from operations.
In multiple years FNA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: FNA reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.89%, FNA is in line with its industry, outperforming 51.34% of the companies in the same industry.
FNA's Return On Equity of -45.24% is in line compared to the rest of the industry. FNA outperforms 49.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.89% | ||
| ROE | -45.24% | ||
| ROIC | N/A |
ROA(3y)-15.46%
ROA(5y)-7.89%
ROE(3y)-27.27%
ROE(5y)-13.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 75.22%, FNA belongs to the best of the industry, outperforming 86.63% of the companies in the same industry.
In the last couple of years the Gross Margin of FNA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for FNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.05%
GM growth 5YN/A
2. Health
2.1 Basic Checks
FNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
FNA has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FNA is higher compared to a year ago.
2.2 Solvency
FNA has an Altman-Z score of 3.27. This indicates that FNA is financially healthy and has little risk of bankruptcy at the moment.
FNA's Altman-Z score of 3.27 is fine compared to the rest of the industry. FNA outperforms 67.91% of its industry peers.
FNA has a Debt/Equity ratio of 0.79. This is a neutral value indicating FNA is somewhat dependend on debt financing.
FNA has a worse Debt to Equity ratio (0.79) than 74.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.27 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
FNA has a Current Ratio of 3.50. This indicates that FNA is financially healthy and has no problem in meeting its short term obligations.
FNA has a better Current ratio (3.50) than 60.43% of its industry peers.
FNA has a Quick Ratio of 1.60. This is a normal value and indicates that FNA is financially healthy and should not expect problems in meeting its short term obligations.
FNA's Quick ratio of 1.60 is on the low side compared to the rest of the industry. FNA is outperformed by 60.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.5 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The earnings per share for FNA have decreased strongly by -48.98% in the last year.
The Revenue has grown by 18.16% in the past year. This is quite good.
FNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.92% yearly.
EPS 1Y (TTM)-48.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y24.92%
Revenue growth 5YN/A
Sales Q2Q%18.11%
3.2 Future
FNA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.10% yearly.
FNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.51% yearly.
EPS Next Y-16.95%
EPS Next 2Y8.08%
EPS Next 3Y14.64%
EPS Next 5Y6.1%
Revenue Next Year16.34%
Revenue Next 2Y16.35%
Revenue Next 3Y16.22%
Revenue Next 5Y18.51%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
FNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FNA's earnings are expected to grow with 14.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.08%
EPS Next 3Y14.64%
5. Dividend
5.1 Amount
FNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PARAGON 28 INC
NYSE:FNA (11/21/2024, 8:04:01 PM)
After market: 10.43 0 (0%)10.43
+0.08 (+0.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap873.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.89% | ||
| ROE | -45.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.22% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.5 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-48.98%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-16.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.16%
Revenue growth 3Y24.92%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y